Wall Street Zen upgraded shares of Atea Pharmaceuticals (NASDAQ:AVIR – Free Report) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.
Several other research firms also recently weighed in on AVIR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley upped their price target on Atea Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.
Check Out Our Latest Stock Report on Atea Pharmaceuticals
Atea Pharmaceuticals Price Performance
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.15. As a group, analysts anticipate that Atea Pharmaceuticals will post -1.99 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC increased its stake in Atea Pharmaceuticals by 80.4% during the 1st quarter. Jane Street Group LLC now owns 102,607 shares of the company’s stock worth $307,000 after buying an additional 45,716 shares during the period. Rhumbline Advisers grew its stake in shares of Atea Pharmaceuticals by 2.6% in the second quarter. Rhumbline Advisers now owns 119,420 shares of the company’s stock worth $430,000 after acquiring an additional 2,977 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Atea Pharmaceuticals by 6.7% in the second quarter. American Century Companies Inc. now owns 173,791 shares of the company’s stock worth $626,000 after acquiring an additional 10,930 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Atea Pharmaceuticals during the second quarter worth $36,000. Finally, Walleye Capital LLC purchased a new stake in shares of Atea Pharmaceuticals during the second quarter worth $208,000. Hedge funds and other institutional investors own 86.67% of the company’s stock.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.
Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.
Featured Stories
- Five stocks we like better than Atea Pharmaceuticals
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
